Mechanism of Action
Uncontrolled JAK/STAT signalling is characteristic of both polycythaemia vera (PV) 1–5 a nd for myelofibrosis (MF). 6
JAKs are tyrosine kinases that transmit signals from cytokine or growth factor receptors to the cell...Twitter Linkedin Facebook Pinterest Google plusEfficacy
Wet AMD Visual acuity and outcomes with Beovu in clinical trialsAt Week 48, brolucizumab demonstrated non-inferiority to aflibercept in mean BCVA change from baseline in HAWK (p<0.001). • Visual acuity gains achieved at Week 48...
Twitter Linkedin Facebook Pinterest Google plusSafety profile
▼Beovu ® (brolucizumab) is indicated in adults for the treatment of neovascular (wet) AMD and visual impairment due to DME 1 Safety profile with Beovu in clinical trials Beovu exhibited an overall well-tolerated safety...
Twitter Linkedin Facebook Pinterest Google plusMechanism of Action
Reimbursement / eHealth
Beovu® (brolucizumab) is reimbursed in Grand-Duché de Luxembourg, not in Belgium.
Twitter Linkedin Facebook Pinterest Google plusPatient Resources
Entresto® (Sacubitril/Valsartan)
ENTRESTO ® is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction. ENTRESTO ® is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure...Twitter Linkedin Facebook Pinterest Google plusPIONEER-HF
The recently presented PIONEER-HF studies the efficacy and safety of initiating ENTRESTO compared to enalapril prior to discharge after hospitalization for an acute decompensated heart failure episode. 1 The results of PIONEER-HF...
Twitter Linkedin Facebook Pinterest Google plusEfficacité
1. Lignes directrices pour le traitementAu cours des dix dernières années, le paysage thérapeutique de la spondylarthrite ankylosante s'est considérablement modifié, avec l'apparition de nouvelles thérapies et de nouveaux modes d'...
Twitter Linkedin Facebook Pinterest Google plus